• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

文本干预以减轻接受免疫检查点抑制剂治疗的癌症患者负担的准确性。

Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors.

机构信息

Abramson Cancer Center, University of Pennsylvania, Philadelphia.

Penn Center for Cancer Care Innovation, University of Pennsylvania, Philadelphia.

出版信息

JAMA Netw Open. 2022 Aug 1;5(8):e2228452. doi: 10.1001/jamanetworkopen.2022.28452.

DOI:10.1001/jamanetworkopen.2022.28452
PMID:36036938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9425147/
Abstract

This cross-sectional study examines whether patients with cancer without symptoms of immune checkpoint inhibitor toxic effects can be accurately identified using a text message–based triage instrument and safely proceed to treatment.

摘要

本横断面研究旨在探讨，是否可以使用基于短信的分诊工具准确识别出无免疫检查点抑制剂毒性作用症状的癌症患者，并安全地进行治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/9425147/435ef6d9130b/jamanetwopen-e2228452-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/9425147/435ef6d9130b/jamanetwopen-e2228452-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2f/9425147/435ef6d9130b/jamanetwopen-e2228452-g001.jpg

相似文献

1
Accuracy of a Text Intervention to Minimize the Burden of Cancer Care Among Patients Treated With Immune Checkpoint Inhibitors.文本干预以减轻接受免疫检查点抑制剂治疗的癌症患者负担的准确性。
JAMA Netw Open. 2022 Aug 1;5(8):e2228452. doi: 10.1001/jamanetworkopen.2022.28452.
2
Immunotherapy and predictive immunologic profile: the tip of the iceberg.免疫治疗和预测性免疫特征：冰山一角。
Med Oncol. 2021 Mar 31;38(5):51. doi: 10.1007/s12032-021-01497-8.
3
Resistance mechanisms to checkpoint inhibitors.针对检查点抑制剂的耐药机制。
Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 3.
4
Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).靶向免疫检查点分子的纳米抗体用于肿瘤免疫治疗和免疫成像（综述）。
Int J Mol Med. 2021 Feb;47(2):444-454. doi: 10.3892/ijmm.2020.4817. Epub 2020 Dec 14.
5
Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.介入治疗联合免疫检查点抑制剂：免疫治疗时代癌症治疗的新机遇。
Cancer Treat Rev. 2019 Mar;74:49-60. doi: 10.1016/j.ctrv.2018.08.006. Epub 2018 Aug 20.
6
Blood neutrophil subset predicts the success of immune checkpoint inhibitors in cancer.血液中性粒细胞亚群可预测癌症免疫检查点抑制剂的疗效。
Nat Rev Immunol. 2024 Feb;24(2):89. doi: 10.1038/s41577-024-00993-y.
7
A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden.用于量化患者对检查点抑制剂的敏感性和长期肿瘤负担的数学模型。
Nat Biomed Eng. 2021 Apr;5(4):297-308. doi: 10.1038/s41551-020-00662-0. Epub 2021 Jan 4.
8
Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors.社论：免疫检查点抑制剂因年龄和性别因素产生的差异疗效
Front Immunol. 2022 Jun 16;13:941254. doi: 10.3389/fimmu.2022.941254. eCollection 2022.
9
Fighting ageing with immune checkpoint blockade.用免疫检查点阻断疗法对抗衰老。
Nat Rev Drug Discov. 2023 Jan;22(1):17. doi: 10.1038/d41573-022-00194-z.
10
[Hepatotoxicity associated with tumor immune checkpoint inhibitors].[与肿瘤免疫检查点抑制剂相关的肝毒性]
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):175-178. doi: 10.3760/cma.j.issn.1007-3418.2020.02.016.

引用本文的文献

1
A Text Message Intervention to Minimize the Time Burden of Cancer Care.一种旨在减轻癌症护理时间负担的短信干预措施。
NEJM Catal Innov Care Deliv. 2025 Mar;6(3). doi: 10.1056/cat.24.0201. Epub 2025 Feb 19.
2
Patient, Caregiver, and Clinician Perspectives on the Time Burdens of Cancer Care.患者、照护者和临床医生对癌症护理时间负担的看法。
JAMA Netw Open. 2024 Nov 4;7(11):e2447649. doi: 10.1001/jamanetworkopen.2024.47649.
3
Financial Toxicity, Time Toxicity, and Quality of Life in Multiple Myeloma.多发性骨髓瘤的财务毒性、时间毒性和生活质量。

本文引用的文献

1
The Time Toxicity of Cancer Treatment.癌症治疗的时间毒性
J Clin Oncol. 2022 May 20;40(15):1611-1615. doi: 10.1200/JCO.21.02810. Epub 2022 Mar 2.
2
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.抗PD-1/PD-L1治疗恶性肿瘤相关的免疫相关不良事件：一项荟萃分析。
Front Pharmacol. 2017 Oct 18;8:730. doi: 10.3389/fphar.2017.00730. eCollection 2017.
3
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.
Clin Lymphoma Myeloma Leuk. 2024 Jul;24(7):446-454.e3. doi: 10.1016/j.clml.2024.02.013. Epub 2024 Feb 23.
4
Consuming Patients' Days: Time Spent on Ambulatory Appointments by People With Cancer.消耗患者的时间：癌症患者门诊预约所花费的时间
Oncologist. 2024 May 3;29(5):400-406. doi: 10.1093/oncolo/oyae016.
常规癌症治疗期间通过患者报告结局进行症状监测：一项随机对照试验。
J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7.
4
What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials.常规使用患者报告结局测量对改善癌症护理患者结局、护理过程和卫生服务结局的价值是什么？一项对照试验的系统评价。
J Clin Oncol. 2014 May 10;32(14):1480-501. doi: 10.1200/JCO.2013.53.5948. Epub 2014 Apr 7.
5
Electronic self-report assessment for cancer and self-care support: results of a multicenter randomized trial.电子自我报告评估在癌症和自我护理支持中的应用：一项多中心随机试验的结果。
J Clin Oncol. 2014 Jan 20;32(3):199-205. doi: 10.1200/JCO.2013.48.6662. Epub 2013 Dec 16.